Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer

Medicine and Dentistry

• Lung Cancer 100%
• Entrectinib 100%
• Central Nervous System Metastasis 60%
• Central Nervous System 40%
• Adverse Event 20%
• Progression Free Survival 20%
• Tyrosine-Kinase Inhibitor 20%
• Gene Mutation 20%
• Proteus Syndrome 20%
• Systemic Therapy 20%
• Subgroup Analysis 20%
• Chimeric Protein 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Cancer 100%
• Entrectinib 100%
• Central Nervous System Metastasis 60%
• Adverse Event 20%
• Multiple Cancer 20%
• Progression Free Survival 20%
• Protein Tyrosine Kinase Inhibitor 20%
• Chimeric Protein 20%

Neuroscience

• Central Nervous System 100%
• Tyrosine Kinase Inhibitor 20%
• Gene Mutation 20%
• Chimeric Protein 20%